SS Innovations International, Inc. (SSII) Gains Approvals for SSi Mantra in Key Emerging Markets

We recently compiled a list of the 12 Penny Stocks with Insider Buying in 2026. SS Innovations International, Inc. is one of the best stocks with Insider buying on this list.

TheFly reported on March 30 that SSII announced that its SSi Mantra surgical robotic system obtained regulatory approvals for multiple uses in Colombia, Oman, Sri Lanka, and Kenya. The approvals were granted by Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos and Oman’s Directorate General of Pharmaceutical Affairs and Drug Control in November 2025, and by Sri Lanka’s National Medicines Regulatory Authority and Kenya’s Pharmacy and Poisons Board in January 2026. These approvals allow the company to expand the availability of the SSi Mantra system across these international markets for various surgical applications.

Separately, on March 10, SS Innovations International, Inc. (NASDAQ:SSII) released its fourth-quarter and full-year 2025 financial results, reporting $14.5 million in revenue compared with $8.1 million in the prior year. SSi Mantra surgical robotic system installations reached 40 in Q4, up 81.8% from 22 in Q4 2024 and 48.1% from 27 in Q3 2025.SS Innovations International, Inc. (SSII) Gains Approvals for SSi Mantra in Key Emerging Markets

The company expanded its presence in India, entered new international markets, advanced regulatory progress in the U.S. and European Union, and introduced innovations such as the Tele Surgeon Console and MantraM mobile robotic unit. Following the quarter, a private placement raised roughly $18.6 million in gross proceeds, attracting long-term institutional investors. SS Innovations plans to continue scaling the SSi Mantra, expand global reach, and target U.S. FDA and EU CE approvals in 2026.

SS Innovations International, Inc. (NASDAQ:SSII) is a medical technology company developing and commercializing surgical robotic systems and advanced instruments to make robotic surgery more affordable and accessible globally. Its flagship SSi Mantra platform supports a wide range of minimally invasive procedures.

While we acknowledge the potential of SSII as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.

View Comments